A NEW RISK STRATIFICATION STRATEGY IN NEWLY DIAGNOSED MULTIPLE MYELOMA: AN ANALYSIS ON MATURE DATA FROM EUROPEAN CLINICAL TRIALS WITHIN THE HARMONY BIG DATA PLATFORM
Author(s): ,
Mattia D'agostino
Affiliations:
HARMONY,European Network,Italy
,
Juan José Lahuerta
Affiliations:
HARMONY,European Network,Spain
,
Anders Waage
Affiliations:
HARMONY,European Network,Norway
,
Uta Bertsch
Affiliations:
HARMONY,European Network,Germany
,
Elena Zamagni
Affiliations:
HARMONY,European Network,Italy
,
Maria-Victoria Mateos
Affiliations:
HARMONY,European Network,Spain
,
Alessandra Larocca
Affiliations:
HARMONY,European Network,Italy
,
Daniele Dall'Olio
Affiliations:
HARMONY,European Network,Italy
,
Niels WCJ van de Donk
Affiliations:
HARMONY,European Network,Netherlands
,
Hans Salwender
Affiliations:
HARMONY,European Network,Germany
,
Joan Bladé
Affiliations:
HARMONY,European Network,Spain
,
Bronno van der Holt
Affiliations:
HARMONY,European Network,Netherlands
,
Gastone Castellani
Affiliations:
HARMONY,European Network,Italy
,
Giovannino Ciccone
Affiliations:
HARMONY,European Network,Italy
,
Jan Dürig
Affiliations:
HARMONY,European Network,Germany
,
Sara Bringhen
Affiliations:
HARMONY,European Network,Italy
,
Sonja Zweegman
Affiliations:
HARMONY,European Network,Netherlands
,
Michele Cavo
Affiliations:
HARMONY,European Network,Italy
,
Hartmut Goldschmidt
Affiliations:
HARMONY,European Network,Germany
,
Jesús María Hernandez Rivas
Affiliations:
HARMONY,European Network,Spain
,
Jesus San Miguel
Affiliations:
HARMONY,European Network,Spain
,
Mario Boccadoro
Affiliations:
HARMONY,European Network,Italy
Pieter Sonneveld
Affiliations:
HARMONY,European Network,Netherlands
EHA Library. D'Agostino M. 06/12/20; 294850; EP933
Dr. Mattia D'Agostino
Dr. Mattia D'Agostino
Contributions
Abstract

Abstract: EP933

Type: e-Poster

Presentation during EHA25: All e-Poster presentations will be made available on the on-demand Virtual Congress platform as of Friday, June 12 at 08:30 CEST and will be accessible until October 15, 2020.

Background

The Revised-ISS (R-ISS) is a risk stratification model for newly diagnosed (ND) multiple myeloma (MM) integrating International Staging System (ISS), high risk chromosomal abnormalities [del(17), t(4;14) or t(14;16)] and LDH. Yet, 60% of patients (pts) are considered as intermediate-risk (R-ISS2), possibly including pts with different risk of progression/death. We previously showed that t(14;16) was not an independent predictor of survival within the R-ISS and we identified other features currently not included in the R-ISS [amp(1q), IgA isotype, impaired renal function, poor performance status] predicting a worse OS (D’Agostino et al. ASH 2019).

Aims

Our aim was to develop an improved prognostic scoring system for NDMM.

Methods
Data from 14 European clinical trials enrolling NDMM pts were collected through the European Myeloma Network and registered in HARMONY platform, a European public-private partnership focusing on hematologic malignancies with unmet medical needs. OMOP Common Data Model was used to harmonize data. All pts received an immunomodulatory agent (IMiD) and/or a proteasome inhibitor (PI) upfront. In a multivariate Cox regression analysis adjusted for age, sex and therapy, the impact of each risk feature on pts’ survival was evaluated. The hazard ratio for death of each variable was used to create an additive risk score.

Results

1258 pts had complete data on the analyzed risk features and were included in the analysis. Median follow-up was 72 months; median age was 62 years. The majority of pts were transplant-eligible (71%). 40% received IMiDs only, 19% PIs only, 41% both drug classes.

In a multivariate Cox model, ISS2 (HR 1.72, p<0.001), ISS3 (HR 2.14, p<0.001), del(17p) (HR 1.77, p<0.001), t(4;14) (HR 1.52, p<0.001), amp(1q) (HR 1.48, p<0.001), high LDH (HR 1.52, p<0.001) and poor performance status (ECOG >1 or Karnofsky <80, HR 1.63, p<0.001) confirmed to be independent OS predictors, while IgA isotype (HR 1.03, p=0.77) and impaired renal function (creatinine clearance ≤45 ml/min, HR 1.21, p=0.11) did not.

Among these, we selected only disease-related factors and exploited their impact on OS to create a scoring system (Table 1).

Pts were stratified into 4 groups with significantly different OS (Figure 1A) and PFS (Figure 1B): Low [(n=232 (18.4%), score 0)], Low-Intermediate [(n=384 (30.5%), score 0.5-1], Intermediate-High [(n=525 (41.7%), score 1.5-2.5] and High [(n=117 (9.3%), score 3-5].

Median OS was not reached vs 91.7 vs 63.8 vs 32.2 months and median PFS was 62.5 vs 38.7 vs 27 vs 18.2 months in the above 4 risk groups, respectively.

R-ISS2 pts (n=770) were reclassified into Low-intermediate (n=289), Intermediate-High (n=456) and High risk (n=25) groups, thus confirming that this wide group included pts with a different risk of progression and/or death. 

The new risk stratification maintained its prognostic value in transplant-eligible, transplant-ineligible, IMiD-treated and PI-treated pts.

The survival disadvantage of Low-Intermediate vs Low risk pts was overcome in pts treated with a first-line therapy including a PI and an IMiD (HR 1.21, p= 0.513), while High-intermediate and High risk group still showed a dismal survival.

Conclusion

Our new scoring system improves risk stratification in NDMM, representing a possible first step towards a risk-adapted approach. Such additive risk score easily allows the inclusion of new prognostic variables in the future. Validation in an independent cohort is ongoing.

Session topic: 14. Myeloma and other monoclonal gammopathies - Clinical

Abstract: EP933

Type: e-Poster

Presentation during EHA25: All e-Poster presentations will be made available on the on-demand Virtual Congress platform as of Friday, June 12 at 08:30 CEST and will be accessible until October 15, 2020.

Background

The Revised-ISS (R-ISS) is a risk stratification model for newly diagnosed (ND) multiple myeloma (MM) integrating International Staging System (ISS), high risk chromosomal abnormalities [del(17), t(4;14) or t(14;16)] and LDH. Yet, 60% of patients (pts) are considered as intermediate-risk (R-ISS2), possibly including pts with different risk of progression/death. We previously showed that t(14;16) was not an independent predictor of survival within the R-ISS and we identified other features currently not included in the R-ISS [amp(1q), IgA isotype, impaired renal function, poor performance status] predicting a worse OS (D’Agostino et al. ASH 2019).

Aims

Our aim was to develop an improved prognostic scoring system for NDMM.

Methods
Data from 14 European clinical trials enrolling NDMM pts were collected through the European Myeloma Network and registered in HARMONY platform, a European public-private partnership focusing on hematologic malignancies with unmet medical needs. OMOP Common Data Model was used to harmonize data. All pts received an immunomodulatory agent (IMiD) and/or a proteasome inhibitor (PI) upfront. In a multivariate Cox regression analysis adjusted for age, sex and therapy, the impact of each risk feature on pts’ survival was evaluated. The hazard ratio for death of each variable was used to create an additive risk score.

Results

1258 pts had complete data on the analyzed risk features and were included in the analysis. Median follow-up was 72 months; median age was 62 years. The majority of pts were transplant-eligible (71%). 40% received IMiDs only, 19% PIs only, 41% both drug classes.

In a multivariate Cox model, ISS2 (HR 1.72, p<0.001), ISS3 (HR 2.14, p<0.001), del(17p) (HR 1.77, p<0.001), t(4;14) (HR 1.52, p<0.001), amp(1q) (HR 1.48, p<0.001), high LDH (HR 1.52, p<0.001) and poor performance status (ECOG >1 or Karnofsky <80, HR 1.63, p<0.001) confirmed to be independent OS predictors, while IgA isotype (HR 1.03, p=0.77) and impaired renal function (creatinine clearance ≤45 ml/min, HR 1.21, p=0.11) did not.

Among these, we selected only disease-related factors and exploited their impact on OS to create a scoring system (Table 1).

Pts were stratified into 4 groups with significantly different OS (Figure 1A) and PFS (Figure 1B): Low [(n=232 (18.4%), score 0)], Low-Intermediate [(n=384 (30.5%), score 0.5-1], Intermediate-High [(n=525 (41.7%), score 1.5-2.5] and High [(n=117 (9.3%), score 3-5].

Median OS was not reached vs 91.7 vs 63.8 vs 32.2 months and median PFS was 62.5 vs 38.7 vs 27 vs 18.2 months in the above 4 risk groups, respectively.

R-ISS2 pts (n=770) were reclassified into Low-intermediate (n=289), Intermediate-High (n=456) and High risk (n=25) groups, thus confirming that this wide group included pts with a different risk of progression and/or death. 

The new risk stratification maintained its prognostic value in transplant-eligible, transplant-ineligible, IMiD-treated and PI-treated pts.

The survival disadvantage of Low-Intermediate vs Low risk pts was overcome in pts treated with a first-line therapy including a PI and an IMiD (HR 1.21, p= 0.513), while High-intermediate and High risk group still showed a dismal survival.

Conclusion

Our new scoring system improves risk stratification in NDMM, representing a possible first step towards a risk-adapted approach. Such additive risk score easily allows the inclusion of new prognostic variables in the future. Validation in an independent cohort is ongoing.

Session topic: 14. Myeloma and other monoclonal gammopathies - Clinical

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies